- Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units
- Each unit consists of one common share and one share purchase warrant
- Proceeds from the offering will be used to pay current filing and regulatory fees, reduce debt, and begin production of ACP-01
- Hemostemix is an autologous stem cell therapy company
- Shares of Hemostemix Inc. (HEM) opened trading at C$0.35
Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
Each unit consists of one common share and one share purchase warrant. Each warrant will entitle the holder to acquire one additional common share for $0.55 for 24 months.
Warrants are subject to an acceleration clause.
Proceeds from the offering will be used to pay current filing and regulatory fees, reduce debt and begin production of ACP-01.
All securities issued will be subject to a four-month hold period.
Hemostemix is an autologous stem cell therapy company. The company has developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
Shares of Hemostemix Inc. (HEM) opened trading at C$0.35.
